Surety Medicine 
Competent Medical Authorities for surety operations should be aware of differences between DSM-IV-TR and DSM-5.  

Competent Medical Authorities for surety operations should be aware of differences between the revised
Fourth and Fifth Editions of the American Psychiatric Association's Diagnostic and Statistical Manual
of Mental Disorders (DSM).                                                             
                                                                                                                           - Surety Medicine image

September 2017 Surety Medicine Teleconference:

Abuse, Dependence and Substance Use 
Disorders:  DSM-IV-TR vs. DSM-5 

WEDNESDAY, 27 September 2017 will bring the next Surety Medicine Teleconference, at 1 pm (1300 hrs) Eastern Time.  The topic for September is "Abuse, Dependence and Substance Use Disorders:  DSM-IV-TR vs. DSM-5.”  This discussion of Army surety medical support considerations related to different versions of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders will be led by the Army Public Health Center's senior occupational health physician. 

To receive access information for attending the presentation by dial-in phone audio or on your computer via Defense Collaboration Services (DCS), send an email request to:

usarmy.apg.medcom-aphc.mbx.surety-medicine@mail.mil

______________________________________________________________

New!
SCHEDULE OF SURETY MEDICINE TELECONFERENCES FOR FY 2018

18 OCT 2017

Updates on Patient Decontamination and the Use of RSDL

15 NOV 2017

Emergency Essential Civilian Employees and the PRP

13 DEC 2017

Diagnosis/Evaluation/Treatment of Laboratory Acquired Alpha Virus Infections

17 JAN 2018

Screening for Dementia and Cognitive Impairments:  PRP Suitability & Reliability

21 FEB 2018

Ergonomics and the Personnel Reliability Program

21 MAR 2018

Updates in the Diagnosis and Treatment of Nerve & Vesicant Agent Exposures

18 APR 2018

Hearing Conservation and Audiometric Testing in Surety Programs 

16 MAY 2018

HIV:  CD4 Counts, Antiretroviral Drugs, and Impaired Immune Functions in PRP

27 JUN 2018

Medical Review Officer Functions, and Relevant PRP Interfaces

18 JUL 2018

Screening Diabetics for Reliability and Suitability in the PRP

15 AUG 2018

Case Studies in Personnel Reliability Program Surety Management

26 SEP 2018

Animal Worker Occupational Health Issues in the PRP

______________________________________________________________________________

ALERT:  FDA Simplifies Rule for Anthrax PEP

FDA APPROVES ANTHRAX VACCINE FOR POST-EXPOSURE PROPHYLAXIS

The US Food and Drug Administration (FDA) has approved the current Anthrax Vaccine Adsorbed for use in combination with antibiotic therapy after a confirmed or suspected exposure to Bacillus anthracis, the causative agent for anthrax.  The vaccine had been approved in 1970 for pre-exposure protection of those who might be exposed to the organism, but this recent approval for use in post-exposure prophylaxis (PEP) approves the use of the vaccine in combination with selected antibiotics to significantly improve the chances of survival in patients exposed to inhaled anthrax, without the previously required use of an investigational new drug (IND) protocol.

Additional information is available from the FDA at: 

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm474027.htm  


ALERT:  Autoinjector Shelf Life Extension Program:  UPDATED JULY 5, 2017

NERVE AGENT ANTIDOTE SHELF LIFE EXTENSION PROGRAM:  Many expiration date extensions for autoinjector medications expire in 2017! 
Check any auto-injector medication stores you have.  Select the link
below for additional information from the FDA.

The US Food and Drug Administration (FDA) is alerting health care professionals and emergency responders that specific lots of DuoDote combined nerve agent antidote auto-injectors have been approved for shelf life extensions beyond labeled expiration dates, some are now extended to 2022.  Complete FDA information related to the auto-injector shelf life extension program can be found at:  http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm .  

Information on this page also includes the latest updates (4/15/2016) on shelf life
extensions for the AtroPen (atropine), CANA (diazepam), morphine sulfate, and
pralidoxime chloride auto-injectors. 

_______________________________________________________________

Related programs and contacts